Dishman Pharmaceuticals and Chemicals Ltd is planning to shift its focus from low-margin to high-margin products in a bid to boost profits. The company is also re-structuring its Carbogen Amcis subsidiary to bring it back on a growth track.
Business Standard
Thursday, 16 June 2011
Dishman shifts focus
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment